Trial Profile
A Phase II Study of Sunitinib (NSC 736511, IND 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Anaplastic astrocytoma; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Therapeutic Use
- 14 Apr 2021 A population pharmacokinetic model was developed for sunitinib and SU012662 in pediatric patients with GIST or other solid tumors, results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 26 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Apr 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center; 13-026).